StreetInsider.com News Articles

HanchorBio and Taiwan Cancer Moonshot Project-NTU Subteam Led by Professor Sung-Liang Yu Establish Strategic Collaboration to Advance Precision Oncology

Sun, 09 Aug 2026 22:26:00 -0400

Collaboration connects internationally recognized cancer multi-omics research with HanchorBio's clinical-stage immuno-oncology platform to accelerate biomarker-driven drug development and strengthen next-generation precision immunotherapy

TAIPEI and SHANGHAI and SAN FRANCISCO, Aug. 9, 2026 /PRNewswire/ -- HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies for oncology and immune-mediated diseases, today announced that its wholly owned Taiwan subsidiary has entered into a strategic collaboration with the research team led by Professor Sung-Liang Yu of National Taiwan University, a key participating team in the

HanchorBio and Taiwan Cancer Moonshot Project-NTU Subteam Led by Professor Sung-Liang Yu Establish Strategic Collaboration to Advance Precision Oncology

Sun, 09 Aug 2026 22:26:00 -0400

HanchorBio and Taiwan Cancer Moonshot Project-NTU Subteam Led by Professor Sung-Liang Yu Establish Strategic Collaboration to Advance Precision Oncology

Sun, 09 Aug 2026 22:26:00 -0400

HanchorBio and Taiwan Cancer Moonshot Project-NTU Subteam Led by Professor Sung-Liang Yu Establish Strategic Collaboration to Advance Precision Oncology

Sun, 09 Aug 2026 22:26:00 -0400

HanchorBio and Taiwan Cancer Moonshot Project-NTU Subteam Led by Professor Sung-Liang Yu Establish Strategic Collaboration to Advance Precision Oncology

Sun, 09 Aug 2026 22:26:00 -0400

HanchorBio and Taiwan Cancer Moonshot Project-NTU Subteam Led by Professor Sung-Liang Yu Establish Strategic Collaboration to Advance Precision Oncology

Sun, 09 Aug 2026 22:26:00 -0400

HanchorBio and Taiwan Cancer Moonshot Project-NTU Subteam Led by Professor Sung-Liang Yu Establish Strategic Collaboration to Advance Precision Oncology

Sun, 09 Aug 2026 22:26:00 -0400

HanchorBio and Taiwan Cancer Moonshot Project-NTU Subteam Led by Professor Sung-Liang Yu Establish Strategic Collaboration to Advance Precision Oncology

Sun, 09 Aug 2026 22:26:00 -0400

HanchorBio and Taiwan Cancer Moonshot Project-NTU Subteam Led by Professor Sung-Liang Yu Establish Strategic Collaboration to Advance Precision Oncology

Sun, 09 Aug 2026 22:26:00 -0400

HanchorBio and Taiwan Cancer Moonshot Project-NTU Subteam Led by Professor Sung-Liang Yu Establish Strategic Collaboration to Advance Precision Oncology

Sun, 09 Aug 2026 22:26:00 -0400

HanchorBio Tests Broader Ambitions for HCB101 Through InxMed Partnership

Wed, 08 Jul 2026 21:13:00 -0400

Taiwan-listed biotech looks to expand the value of its lead oncology asset through combination research with late-stage cancer drug resistance specialist InxMed.

TAIPEI and SHANGHAI and SAN FRANCISCO, July 8, 2026 /PRNewswire/ -- HanchorBio, Inc. (TWSE: 7827) is taking another step to broaden the development path for HCB101, its lead oncology asset, through a new partnership with InxMed.

The Taiwan-listed clinical-stage biotech announced that its subsidiary, FBD Biologics Limited, has signed a strategic memorandum of understanding (MOU) with InxMed (Shanghai)

HanchorBio Tests Broader Ambitions for HCB101 Through InxMed Partnership

Wed, 08 Jul 2026 21:13:00 -0400

Taiwan-listed biotech looks to expand the value of its lead oncology asset through combination research with late-stage cancer drug resistance specialist InxMed.

The Taiwan-listed clinical-stage biotech announced that its subsidiary, FBD Biologics Limited, has signed a strategic memorandum of understanding (MOU) with InxMed (Shanghai)

HanchorBio to List on Taiwan Innovation Board at NT$120 per Share as HCB101 Clinical Data Support Global Partnering Discussions

Thu, 28 May 2026 06:00:00 -0400

Global clinical-stage biotech x FBDB™ platform and multi-indication development strategy for lead program HCB101

TAIPEI, SHANGHAI, SAN FRANCISCO, May 28, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that it will be officially listed on the Taiwan Innovation Board on May 29, 2026, with an underwriting price of NT$120 per share.

HanchorBio is focused on developing differentiated immunotherapies targeting large unmet needs in oncology and autoimmune diseases. The Company's core technology is its proprietary FBDB™ platform,

HanchorBio to List on Taiwan Innovation Board at NT$120 per Share as HCB101 Clinical Data Support Global Partnering Discussions

Thu, 28 May 2026 06:00:00 -0400

Global clinical-stage biotech x FBDB™ platform and multi-indication development strategy for lead program HCB101

HanchorBio is focused on developing differentiated immunotherapies targeting large unmet needs in oncology and autoimmune diseases. The Company's core technology is its proprietary FBDB™ platform,

HanchorBio Prices IPO at NT$120 Ahead of Innovation Board Listing on May 29

Tue, 26 May 2026 04:00:00 -0400

TAIPEI and SHANGHAI and SAN FRANCISCO, May 26, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced the completion of bookbuilding for its initial public offering on the Taiwan Innovation Board. The offering price has been set at NT$120 per share. HanchorBio is expected to list on the Taiwan Innovation Board on May 29, 2026.

The offering attracted strong interest from domestic and international institutional investors and was oversubscribed. As part of the

HanchorBio Prices IPO at NT$120 Ahead of Innovation Board Listing on May 29

Tue, 26 May 2026 04:00:00 -0400

The offering attracted strong interest from domestic and international institutional investors and was oversubscribed. As part of the

HanchorBio Selects Bloomberg to Strengthen its Strategic Intelligence Across Drug Development and Global Biopharma

Fri, 24 Apr 2026 07:30:00 -0400

Expanding HanchorBio's data-enabled approach from molecule design to portfolio and market insight

TAIPEI and SHANGHAI and SAN FRANCISCO, April 24, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for immuno-oncology and immune-related diseases, today announced it has selected Bloomberg to support strategic decision-making across portfolio planning, pipeline development, competitive monitoring, business development, and capital markets activities.

Through access to Bloomberg's data and research content, including Bloomberg Intelligence's Disease dashboard via

HanchorBio Selects Bloomberg to Strengthen its Strategic Intelligence Across Drug Development and Global Biopharma

Fri, 24 Apr 2026 07:30:00 -0400

Expanding HanchorBio's data-enabled approach from molecule design to portfolio and market insight

Through access to Bloomberg's data and research content, including Bloomberg Intelligence's Disease dashboard via

HanchorBio Selects Bloomberg to Strengthen its Strategic Intelligence Across Drug Development and Global Biopharma

Fri, 24 Apr 2026 07:30:00 -0400

Expanding HanchorBio's data-enabled approach from molecule design to portfolio and market insight

Through access to Bloomberg's data and research content, including Bloomberg Intelligence's Disease dashboard via

HanchorBio Selects Bloomberg to Strengthen its Strategic Intelligence Across Drug Development and Global Biopharma

Fri, 24 Apr 2026 07:30:00 -0400

Expanding HanchorBio's data-enabled approach from molecule design to portfolio and market insight

Through access to Bloomberg's data and research content, including Bloomberg Intelligence's Disease dashboard via

HanchorBio Selects Bloomberg to Strengthen its Strategic Intelligence Across Drug Development and Global Biopharma

Fri, 24 Apr 2026 07:30:00 -0400

Expanding HanchorBio's data-enabled approach from molecule design to portfolio and market insight

Through access to Bloomberg's data and research content, including Bloomberg Intelligence's Disease dashboard via

HanchorBio Selects Bloomberg to Strengthen its Strategic Intelligence Across Drug Development and Global Biopharma

Fri, 24 Apr 2026 07:30:00 -0400

Expanding HanchorBio's data-enabled approach from molecule design to portfolio and market insight

Through access to Bloomberg's data and research content, including Bloomberg Intelligence's Disease dashboard via

HanchorBio Advances Toward TWSE Innovation Board Listing to Accelerate Global Clinical Development, Platform Expansion, and International Partnering

Wed, 25 Mar 2026 06:00:00 -0400

Listing milestone positions HanchorBio to strengthen institutional visibility, advance its FBDB™ platform, and expand a growing pipeline spanning oncology and broader immune-mediated diseases

TAIPEI, SHANGHAI and SAN FRANCISCO, March 25, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation multifunctional biologics across oncology and immune-related diseases, today announced that it has received approval from the Board of Directors of the Taiwan Stock Exchange to list on the TWSE Innovation Board, with listing anticipated in the second quarter

HanchorBio Advances Toward TWSE Innovation Board Listing to Accelerate Global Clinical Development, Platform Expansion, and International Partnering

Wed, 25 Mar 2026 06:00:00 -0400

Listing milestone positions HanchorBio to strengthen institutional visibility, advance its FBDB™ platform, and expand a growing pipeline spanning oncology and broader immune-mediated diseases

HanchorBio Advances Toward TWSE Innovation Board Listing to Accelerate Global Clinical Development, Platform Expansion, and International Partnering

Wed, 25 Mar 2026 06:00:00 -0400

Listing milestone positions HanchorBio to strengthen institutional visibility, advance its FBDB™ platform, and expand a growing pipeline spanning oncology and broader immune-mediated diseases